Vitality Watch

Dossier clinicaltrials trial early 01-jul-2026
Small or early-phase human trial or pilot study

Ongoing Lung Decline With Age Intensified Response

Key claim: A Phase II pilot RCT is testing whether short-course high-dose fisetin improves lung function and reduces cellular-senescence biomarkers in adults aged 60+ with and without a smoking history.

Abstract

This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course “hit-and-run” dosing strategy (approximately 20 mg/kg/day orally for 2 consecutive days on Days 1-2 and Days 8-9).

Why this matters

Fisetin’s senolytic reputation has rested largely on animal models and small biomarker-focused human pilots; a Phase II RCT explicitly targeting age-related lung decline — and stratifying by smoking history — is one of the first attempts to tie the senolytic rationale to a clinically meaningful organ-function endpoint in older adults. Because it is a trial launch rather than a readout, the finding shifts the fisetin/senolytics record from mechanism and animal data toward a pending human outcome test, and the gap between senolytic enthusiasm and actual human efficacy data remains until results arrive.

Source

Link

Briefing card

Ongoing Lung Decline With Age Intensified Response
Stage: trial early · clinicaltrials · 01-jul-2026

A Phase II pilot RCT is testing whether short-course high-dose fisetin improves lung function and reduces cellular-senescence biomarkers in adults aged 60+ with and without a smoking history.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07676435

build build 880 · 2bcef25 · 2026-11-18